[Evaluation of urinary NMP22 (nuclear matrix protein 22) as a diagnostic marker for urothelial cancer--NMP22 as a urinary marker for surveillance of bladder cancer. NMP22 Study Group].

@article{Akaza1997EvaluationOU,
  title={[Evaluation of urinary NMP22 (nuclear matrix protein 22) as a diagnostic marker for urothelial cancer--NMP22 as a urinary marker for surveillance of bladder cancer. NMP22 Study Group].},
  author={Hideyuki Akaza and Naoto Miyanaga and Tetsuro Tsukamoto and Shuichi Ishikawa and Ryo Noguchi and Mikinobu Ohtani and Kazuki Kawabe and Yoshinobu Kubota and Kazuyuki Fujita and Koji Obata and Yoshihiko Hirao and Toshihiko Kotake and Hiroyuki Ohmori and Joichi Kumazawa and Kenkichi Koiso},
  journal={Gan to kagaku ryoho. Cancer & chemotherapy},
  year={1997},
  volume={24 7},
  pages={829-36}
}
This study was undertaken to determine the clinical usefulness of NMP22 (Nuclear Matrix Protein 22) as a urinary marker for the surveillance of bladder cancer, especially in comparison with that of voided urine cytology. Urinary NMP22 values were determined for 144 patients with histologically diagnosed bladder cancer, 65 patients with other urological cancers, and 171 healthy volunteers by use of a UNMP22 Test kit, which is based on an enzyme-linked immunosorbent assay. All bladder cancer… CONTINUE READING